VRK1 and cancer: A degrader strategy, as modeled in this current study, may represent an alternative approach to targeting VRK1 as a growing number of small molecule degraders (e.g., PROTACs, molecular glues, etc.)targeting specific proteins are undergoing clinical trials in diverse cancers (32).